RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Conditions: Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors; ERBB2 Gene Duplication; Disitamab Vedotin Interventions: Drug: Disitamab Vedotin; Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib); Drug: pyrotinib Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 29, 2023 Category: Research Source Type: clinical trials
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma Interventions: Drug: Abemaciclib; Drug: Anastrozole; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Diagnostic Imaging; Drug: Exemestane; Other: Fludeoxyglucose F-18; Drug: Fluorine F 18 Fluoro Furanyl Norprogesterone; Drug: Fulvestrant; Biological: Gonadotropin-releasin...
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
A Study of RC48-ADC Combined With Cadonilimab （AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
Conditions: Urothelial Carcinoma Interventions: Drug: RC48-ADC; Drug: AK104 Sponsors: Shanxi Province Cancer Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
Conditions: Biliary Tract Cancer; HER2 Gene Mutation Interventions: Drug: SOC plus trastuzumab and pembrolizumab Sponsors: Institut f ür Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp& Dohme GmbH, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Disitamab Vedotin Injection; Drug: Pertuzumab Injection; Drug: Toripalimab Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS < 5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma Interventions: Drug: M108 monoclonal antibody; Drug: Placebo; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: FutureGen Biopharmaceutical (Beijing) Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
Conditions: Advanced Breast Cancer; Treatment; HR Low/HER2 Negative Interventions: Drug: Experimental: chemotheyapy; Drug: Active Comparator: endocrine therapy Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Conditions: Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer Interventions: Drug: Datopotamab Deruxtecan Sponsors: Sarah Sammons, MD; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
TROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR low, HER2 low or negative breast cancers
TROPION-Breast05 is evaluating... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: Trastuzumab deruxtecan; Drug: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection; Drug: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection Sponsors: MedSIR; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors
Conditions: Breast Cancer Sponsors: Cliniques universitaires Saint-Luc- Universit é Catholique de Louvain; Jules Bordet Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Disitamb Vedotin Sponsors: The First Affiliated Hospital with Nanjing Medical University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Conditions: Breast Cancer Interventions: Drug: Tucatinib; Drug: Trastuzumab; Drug: Pertuzumab Sponsors: The Netherlands Cancer Institute; Seagen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Conditions: HER2-positive Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Genentech ’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone
The inavolisib combination has the potential to address resistance to treatment and poor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 8, 2023 Category: Pharmaceuticals Source Type: clinical trials
